These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22609245)

  • 41. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of disease: HDL metabolism as a target for novel therapies.
    Rader DJ
    Nat Clin Pract Cardiovasc Med; 2007 Feb; 4(2):102-9. PubMed ID: 17245404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
    Santos-Gallego CG; Ibanez B; Badimon JJ
    Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of dyslipidemia in HIV.
    Sekhar RV
    Curr Atheroscler Rep; 2015 Apr; 17(4):493. PubMed ID: 25702057
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
    Wierzbicki AS
    Curr Med Res Opin; 2005 Feb; 21(2):299-306. PubMed ID: 15802001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-density lipoprotein and progression rate of atherosclerosis in intravascular ultrasound trials.
    Nicholls SJ
    Am J Cardiol; 2009 Nov; 104(10 Suppl):16E-21E. PubMed ID: 19895940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-density lipoprotein cholesterol and coronary heart disease.
    Young CE; Karas RH; Kuvin JT
    Cardiol Rev; 2004; 12(2):107-19. PubMed ID: 14766026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should we take high-density lipoprotein cholesterol levels at face value?
    Leite JO; Fernandez ML
    Am J Cardiovasc Drugs; 2010; 10(1):1-3. PubMed ID: 20104929
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
    Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
    J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 53. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The paradox of dysfunctional high-density lipoprotein.
    Ansell BJ; Fonarow GC; Fogelman AM
    Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-density lipoproteins and cardiovascular disease: 2010 update.
    Alwaili K; Awan Z; Alshahrani A; Genest J
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):413-23. PubMed ID: 20222819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases.
    Zhang Y; Luo S; Gao Y; Tong W; Sun S
    Angiology; 2024 May; 75(5):441-453. PubMed ID: 36788038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes.
    Durrington PN
    Evid Based Med; 2015 Feb; 20(1):12. PubMed ID: 25249694
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacogenomics in the development and characterization of atheroprotective drugs.
    Valanti E; Tsompanidis A; Sanoudou D
    Methods Mol Biol; 2014; 1175():259-300. PubMed ID: 25150873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New targets of high-density lipoprotein therapy.
    Nicholls SJ; Nissen SE
    Curr Opin Lipidol; 2007 Aug; 18(4):421-6. PubMed ID: 17620859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.